1. Molecular Diagnostic Yield of Exome Sequencing in Patients With Cerebral Palsy
- Author
-
Vladimir G. Gainullin, Francisca Millan, Claire Teigen, Julie Scuffins, Andres Moreno-De-Luca, Kevin J. Arvai, H. Lester Kirchner, Matthew T. Oetjens, Houda Zghal Elloumi, Scott M. Myers, Karen E. Wain, Kyle Retterer, Rebecca I. Torene, Christa Lese Martin, Denis R. Pesacreta, and David H. Ledbetter
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Cross-sectional study ,01 natural sciences ,Cerebral palsy ,03 medical and health sciences ,0302 clinical medicine ,Neurodevelopmental disorder ,Interquartile range ,Exome Sequencing ,medicine ,Prevalence ,Humans ,030212 general & internal medicine ,Genetic Testing ,0101 mathematics ,Child ,Exome sequencing ,Genetic testing ,Original Investigation ,Retrospective Studies ,Asphyxia ,medicine.diagnostic_test ,business.industry ,Cerebral Palsy ,010102 general mathematics ,Obstetrics and Gynecology ,Genetic Variation ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,Cross-Sectional Studies ,Autism spectrum disorder ,Neurodevelopmental Disorders ,Child, Preschool ,Cohort ,Mutation ,Female ,medicine.symptom ,business - Abstract
Importance Cerebral palsy is a common neurodevelopmental disorder affecting movement and posture that often co-occurs with other neurodevelopmental disorders. Individual cases of cerebral palsy are often attributed to birth asphyxia; however, recent studies indicate that asphyxia accounts for less than 10% of cerebral palsy cases. Objective To determine the molecular diagnostic yield of exome sequencing (prevalence of pathogenic and likely pathogenic variants) in individuals with cerebral palsy. Design, Setting, and Participants A retrospective cohort study of patients with cerebral palsy that included a clinical laboratory referral cohort with data accrued between 2012 and 2018 and a health care–based cohort with data accrued between 2007 and 2017. Exposures Exome sequencing with copy number variant detection. Main Outcomes and Measures The primary outcome was the molecular diagnostic yield of exome sequencing. Results Among 1345 patients from the clinical laboratory referral cohort, the median age was 8.8 years (interquartile range, 4.4-14.7 years; range, 0.1-66 years) and 601 (45%) were female. Among 181 patients in the health care–based cohort, the median age was 41.9 years (interquartile range, 28.0-59.6 years; range, 4.8-89 years) and 96 (53%) were female. The molecular diagnostic yield of exome sequencing was 32.7% (95% CI, 30.2%-35.2%) in the clinical laboratory referral cohort and 10.5% (95% CI, 6.0%-15.0%) in the health care–based cohort. The molecular diagnostic yield ranged from 11.2% (95% CI, 6.4%-16.2%) for patients without intellectual disability, epilepsy, or autism spectrum disorder to 32.9% (95% CI, 25.7%-40.1%) for patients with all 3 comorbidities. Pathogenic and likely pathogenic variants were identified in 229 genes (29.5% of 1526 patients); 86 genes were mutated in 2 or more patients (20.1% of 1526 patients) and 10 genes with mutations were independently identified in both cohorts (2.9% of 1526 patients). Conclusions and Relevance Among 2 cohorts of patients with cerebral palsy who underwent exome sequencing, the prevalence of pathogenic and likely pathogenic variants was 32.7% in a cohort that predominantly consisted of pediatric patients and 10.5% in a cohort that predominantly consisted of adult patients. Further research is needed to understand the clinical implications of these findings.
- Published
- 2021